FDA Off-Label Notice Stands, But Enforcement Still Vulnerable - Judge
Executive Summary
FDA remains vulnerable to future First Amendment challenges if it uses off-label reprints as evidence on misbranding cases, Judge Royce Lamberth suggested in a Nov. 30 court order.
You may also be interested in...
FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
Courts have issued mixed rulings in cases challenging FDA restrictions on drug promotion, but with oral arguments set for July 7, Amarin’s suit could provide a definitive answer on what companies can tell physicians.
Reprinting FDAMA Approach: Waxman Urges FDA Review Of Off-Label Articles
Rep. Henry Waxman, D-Calif., is pushing FDA to require companies to submit reprints of journal articles on off-label use before providing them to practitioners, should the agency go forward with guidance permitting off-label promotion
Reprinting FDAMA Approach: Waxman Urges FDA Review Of Off-Label Articles
Rep. Henry Waxman, D-Calif., is pushing FDA to require companies to submit reprints of journal articles on off-label use before providing them to practitioners, should the agency go forward with guidance permitting off-label promotion